Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial gr...

por Lee, Weon Sup, Shim, Sang Ryeol, Lee, Seon Young, Yoo, Jin San, Cho, Sung Kweon
Publicado 2018

A ligand-independent Tie2-activating antibody reduces vascular leakage in models of Clarkson disease

por Ablooglu, Ararat J., Desai, Abhishek, Yoo, Jin-San, Park, Cheon Ho, Lee, Eun-Ah, Kim, Bu Yeon, Park, Hyunsun, Lee, Young Ae, Shim, Sang Ryeol, Lee, Weon Sup, Druey, Kirk M.
Publicado 2023

Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angioge...

por Kim, Dong Geon, Jin, Younggeon, Jin, Juyoun, Yang, Heekyoung, Joo, Kyeung Min, Lee, Weon Sup, Shim, Sang Ryeol, Kim, Sung-Woo, Yoo, Jinsang, Lee, Sang Hoon, Yoo, Jin-San, Nam, Do-Hyun
Publicado 2015

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

por Lee, Su Jin, Lee, Seon Young, Lee, Weon Sup, Yoo, Jin San, Sun, Jong-Mu, Lee, Jeeyun, Park, Se Hoon, Park, Joon Oh, Ahn, Myung-Ju, Lim, Ho Yeong, Kang, Won Ki, Park, Young Suk
Publicado 2017

An agonistic anti-Tie2 antibody suppresses the normal-to-tumor vascular transition in the glioblastoma invasion zone

por Lee, Eunhyeong, Lee, Eun-Ah, Kong, Eunji, Chon, Haemin, Llaiqui-Condori, Melissa, Park, Cheon Ho, Park, Beom Yong, Kang, Nu Ri, Yoo, Jin-San, Lee, Hyun-Soo, Kim, Hyung-Seok, Park, Sung-Hong, Choi, Seung-Won, Vestweber, Dietmar, Lee, Jeong Ho, Kim, Pilhan, Lee, Weon Sup, Kim, Injune
Publicado 2023